DVA Chart

1 Month

	Date	Diff
	2023-12-04	+2.19 %
The article discusses the impact of Charlie Munger, Warren Buffett's business partner, on the health industry through his investment strategies, particularly with his involvement in Coca-Cola. It highlights the connection between increased sugar consumption, obesity, and diabetes, and how Munger's investments, such as in dialysis provider DaVita, may have influenced the healthcare industry.
	2023-11-30	+1.86 %
DaVita (DVA) stock went up by 1.86% last night, contributing to the overall positive performance of the S&P 500 in November, which saw an 8.9% gain for the index.
	2023-11-14	+4.23 %
The article discusses the U.S. Justice Department's request to dismiss the prosecution of a UnitedHealth Group affiliate accused of unlawfully restricting employee mobility, which is seen as a setback in the government's efforts to apply criminal antitrust laws to labor markets. The reason for the increase in DaVita's stock price is not mentioned in the article.
	2023-11-13	+6.49 %
DaVita HealthCare Partners Inc (NYSE:DVA) stock rose 6.49% because it was one of the top performers in the healthcare sector. Davita Inc (DVA) stock was up 6.49% last night. The article does not provide a specific reason for the increase in the stock. The article mentions that DaVita (DVA) stock went up by 6.49% last night, and the reason for the increase is not specifically mentioned in the article.
	2023-10-26	-1.41 %
The article discusses the potential impact of weight-loss drugs on various industries, including dialysis services providers, medical device makers, retailers, food and beverage companies, and drug distributors. The decline in Davita (DVA) stock may be attributed to the uncertainty surrounding the potential impact of these drugs on the company's kidney dialysis services.
	2023-10-19	+3.66 %
DaVita HealthCare Partners Inc (NYSE:DVA) stock went up 3.66% because it was one of the top performers on the S&P 500. DaVita (DVA) stock went up by 3.66% due to the growing popularity of weight-loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, which may benefit some kidney disease patients and lead to a potential boost in revenues for dialysis services providers like DaVita. The article discusses the potential impact of weight-loss drugs on different sectors, including retailers, food and beverage companies, dialysis service providers, medical device makers, and drug distributors. It mentions that the popularity of weight-loss drugs such as Wegovy and Ozempic could potentially affect sales in these sectors. As a result, companies like Conagra, Walmart, PepsiCo, Fresenius Medical Care, Davita, Johnson & Johnson, Abbott Laboratories, Insulet Corp, and Intuitive Surgical are monitoring the situation and assessing the impact on their businesses. The article does not directly explain why Davita's stock went up by 3.66% the previous night.
	2023-10-18	+3.09 %
Kidney care provider DaVita Inc. (DVA) saw a 3.09% increase in its stock after collaborating with Google Cloud to develop a clinical operating system that improves care plans and streamlines workflows, utilizing Google Cloud's infrastructure, AI, and analytics tools.
	2023-10-13	-0.8 %
The article discusses how Novo Nordisk, a Danish pharmaceutical company, has raised its full-year guidance due to the success of its weight-loss drug Wegovy and diabetes treatment Ozempic, leading to a surge in its share price and making it Europe's most valuable company. The update in sales outlook is primarily driven by higher expectations for Ozempic volumes sold in the U.S. and adjustments in gross-to-net sales for Ozempic and Wegovy in the U.S. As for why Davita (DVA) stock went down, the article does not provide any information on that.
	2023-10-12	-2.77 %
The article discusses the decline in DaVita (DVA) stock, attributing it to the halt of Novo Nordisk's study on its diabetes drug, which negatively impacted kidney-related stocks such as DaVita. The article states that the recent decline in medical technology stocks, including Davita (DVA), in response to GLP-1s (glucagon-like peptide-1 agonists) is overdone and presents an attractive investment opportunity, as these drugs do not reverse disease progression but can slow it down and have associated weight loss benefits. In summary, the article discusses the performance of Davita (DVA) stock, which declined by 2.77% last night. The stock went down due to dialysis firms DaVita and Baxter International slumping as drugmaker Eli Lilly gained following the success of Danish rival Novo Nordisk's trial to treat kidney failure.
	2023-10-11	-16.86 %
The article discusses the recent downgrade of Amgen (AMGN) stock by Leerink Partners analyst David Risinger and the reasons behind it, including an expanding pipeline optionality and potential earnings growth. It does not provide any information regarding Davita (DVA) stock or the reason for its decline. The article states that medical-device stocks, including DaVita Inc. (DVA), are dropping due to the rising popularity of weight loss drugs, which may decrease the need for medical devices that provide insulin and other treatments for diabetes and related conditions. The article discusses how the stock of DaVita Inc. (DVA) went down by 16.86% last night, and the reason for this decline is not specified in the provided excerpt.
	2023-09-19	+2.2 %
The article discusses the recent gain in DaVita Inc (DVA) stock and evaluates whether the stock is undervalued. While the company's financial condition is poor, its profitability and growth are strong, leading to the estimation that the stock is modestly undervalued. The increase in the stock price is likely due to investors recognizing this potential for higher returns.
	2023-09-14	-2.71 %
DaVita HealthCare Partners Inc (DVA) stock went down by 2.71% last night, but the article does not provide a reason for the decline. The article discusses the appointment of Rebecca Steinfort as the non-executive board chair of One Call, a care coordination leader in the workers' compensation industry, and highlights her impressive experience in the healthcare sector. The article does not provide information about why Davita (DVA) stock went down. The article discusses DaVita Inc. (DVA), the largest kidney dialysis treatment provider in the U.S., and its recent stock performance. The stock experienced a 2.71% decrease last night. The reason for the stock decline is not mentioned in the article.
	2023-09-13	+4.09 %
DaVita (DVA) stock went up by 4.09% last night due to positive performance in the healthcare sector.
	2023-09-11	+0.74 %
The article announces that DaVita Inc. (DVA) stock went up by 0.74% after the company's CFO and Vice President of Investor Relations participated in a fireside chat hosted by UBS, where they discussed the company's performance and future prospects.
	2023-09-06	+2.32 %
The article announces that Martha Ha will join US Foods Holding Corp. as Executive Vice President and General Counsel, leading to a 2.32% increase in Davita (DVA) stock. The article discusses the rise of the outpatient and home healthcare industry, which has been driven by the increased demand for telemedicine and AI-powered technology services. DaVita Inc. is one of the companies in this industry that is expected to benefit from these trends. The reason why DaVita's stock went up is not mentioned in the article.
	2023-09-05	-6.16 %
DaVita Inc (DVA) stock experienced a 4.8% daily loss and a 3-month loss of 1.3%, but the company reported an EPS of 5.03. The stock may be modestly undervalued, but the company's financial strength is poor. The stock's profitability and growth are strong compared to others in the industry. The reason for the decline in the stock price is not mentioned in the article.
	2023-08-22	-0.23 %
The article does not provide any information on Davita (DVA) stock or why it went down.
	2023-08-18	+0.91 %
The article discusses Warren Buffett's investment portfolio and highlights the smallest stocks in his portfolio, including DaVita Inc. (DVA). DaVita's stock went up because UBS upgraded its share price rating and increased the share price target.
	2023-08-17	-3.5 %
The article highlights that DaVita (NYSE: DVA) stock has experienced a decline, and the underlying trends indicate that the business may be past the growth phase, with a declining return on capital employed (ROCE) and a declining amount of capital employed. These trends suggest that the company may be struggling and not experiencing much growth in the last five years. The decrease in current liabilities may partly explain the drop in ROCE, as the company is funding more of its operations with its own money. Overall, the article suggests that the current trends do not bode well for long-term performance unless they are reversed.
	2023-08-07	+3.56 %
DaVita Inc (DVA) stock is up 3.56% after UBS upgraded it to "buy" from "neutral" and raised its price target, citing positive earnings estimates and contrarian factors. DaVita (DVA) stock went up by 3.56% after being upgraded to a "buy" rating by UBS, with stronger patient growth cited as a driver for the increase. The article mentions that DaVita (DVA) stock went up 3.56% due to UBS upgrading the stock and raising the price target, citing growth prospects for the kidney dialysis firm. In a recent article, it is reported that DaVita (DVA) stock rose by 3.56% last night. The stock went up after being upgraded to a buy rating by UBS, with the bank citing favorable earnings estimates and a contrarian view as factors supporting the upgrade.
	2023-07-13	-0.95 %
The article announces the appointment of Wendy Schoppert as a new independent director to DaVita Inc.'s Board of Directors, and the stock may have gone down due to unrelated market factors.
	2023-06-27	-1.18 %
InvestorsObserver issued a critical PriceWatch Alert for Davita (DVA) stock, which went down by 1.18%, and the reason for the decline is not mentioned in the article.